Positive Outlook for MDxHealth: Strategic Moves and Undervalued Growth Potential Reinforce Buy RatingWe remain confident in the trajectory of MDxHealth’s business, and, importantly for the stock, of our 2026 targets, which indeed are moving higher following this update. In our view, the business is set up well for what we believe are layers of additional growth opportunities, like that of ExoDx, and for profitability to continue to shine through as operating expenses are held relatively steady.